2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
70
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Docetaxel
292
Prednisone
240
enzalutamide
193
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
169
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
92
gallium 68 PSMA-11
81
abiraterone
81
Specimen Handling
73
darolutamide
65
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
52
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-05-05
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-05-01
DP-04
AstraZeneca
Recruiting
100 enrolled